ReviewCurrent neuropharmacology2026
Current Research Focus and Trends of Remimazolam: A Bibliometric Analysis of the 100 Most Cited Articles.
Review in Current neuropharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionRemimazolam is a novel benzodiazepine derivative with advantages such as prompt onset, short duration of action, fast recovery, and non-organ dependence. Numerous studies have been conducted on remimazolam. However, bibliometric analysis on high-quality and highly cited articles related to remimazolam is lacking. The objective of this article is to evaluate the current research status and prevailing trends regarding the most frequently cited articles on remimazolam, utilizing bibliometrics.
methodsStudies related to remimazolam were searched in the Web of Science core database. The search period ranged from the inception of the database to April 2025, and 100 highly cited research articles were selected. The researchers gathered and analyzed pertinent data from the studies and subsequently conducted visual analysis utilizing VOSviewer and CiteSpace.
resultsThe total number of citations for the top 100 highly cited studies was 6683, published between 2010 and 2024. China, the United States, and the United Kingdom contributed the majority of these studies. These studies were published in 47 different journals. The journal with the highest number of publications was the Journal of Anesthesia. The institution with the highest publication volume was PAION DEUTSCHLAND GMBH in Germany, and the author with the highest contribution was Schippers F. The pharmacokinetics, pharmacodynamics, safety, and efficacy of remimazolam were the main research directions and focuses in the field. DISCUSSION: Our analysis of the top 100 cited remimazolam papers reveals a rapidly advancing field. The surge in high-quality clinical studies confirms remimazolam's practical edge over older agents, such as propofol, particularly in offering better blood pressure stability for older patients and fewer breathing problems during procedures like endoscopy. While these advantages position it as a strong contender, important questions linger about its use in people with severe liver or kidney issues due to how it is broken down, and its effects on delirium remain unclear. Broadening research globally and focusing on these specific patient groups, as well as long-term safety, will be key to realizing remimazolam's full clinical potential.
conclusionThis study analyzed the 100 most frequently referenced articles on remimazolam, providing valuable insights into the characteristics and focal areas of research related to this topic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.